{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001888721,0.002048192,0.00392972,0.0003642701,0.0003985617,0.001190032,0.001040033,0.001955599,0.006115931],"category_scores_gemma":[0.001813224,0.0006418989,0.002398052,0.0004473402,0.00122361,0.001734248,0.0004992737,0.003699146,0.001160924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006621577,"about_ca_system_score_gemma":0.0007472446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006303002,"about_ca_topic_score_gemma":0.00177684,"domain_scores_codex":[0.9993706,0.0003125349,0.00004427225,0.0001202581,0.00003978604,0.0001124714],"domain_scores_gemma":[0.9993926,0.0001683336,0.0001391262,0.00006395531,0.00003728877,0.0001986176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9839544,0.001807635,0.0002983326,0.0008058246,0.001067818,0.00003866036,0.0000430554,0.0002833525,0.001458157,0.0001084207,0.0007803575,0.00935402],"study_design_scores_gemma":[0.9789948,0.01907939,0.0006909075,0.00002465962,0.0003318458,0.00003057579,0.00001609167,0.0001566568,0.000148238,0.0001211176,0.0003945322,0.00001122758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791494,0.01099275,0.0009666611,0.001250608,0.00114067,0.002563554,0.001314681,0.0002169418,0.002404707],"genre_scores_gemma":[0.9827034,0.005118908,0.001378152,0.001517634,0.0004958475,0.002419985,0.001422882,0.00003898927,0.004904132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006115931,"threshold_uncertainty_score":0.02045989,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04734896813518842,"score_gpt":0.3900358492526455,"score_spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}